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that are practiced in the hemodinamy service in the Cardiology
Hospital “Centro Nacional Siglo XXI” in Mexico City.
METHODS: Identiﬁcation of resource use at the hemodinamy
service was realized through expert opinion and the revision of
hospital records during the ﬁrst two months of 2005. Unitary
costs were obtained from the Accounting Department of the hos-
pital. The intervention’s cost estimation was realized with the
technique “case mix” and the perspective was that of the Social
Security Mexican Institute (IMSS). The direct medical costs
included: material of high specialty, medical instruments, drugs,
cineﬂuorscopy and human resources. Indirect medical costs
included: equipment, depreciation, laundry, electricity, tele-
phone, water, etc. Within the estimations of the interventions it
was included the use of counterpulsation balloon, cutting
balloon, glucoproteins (tiroﬁban or abciximab) and trombec-
tomy. RESULTS: Diagnostic catheterism was estimated in
US$328.7. The cost of the other interventions shifted in function
of the type of the stent used (conventional or medical). Inter-
vention of one vessel with conventional stent resulted in
US$1182.5; and with medical stent this raised to US$3438.5.
Also, intervention costs of one vessel trombectomy + counter-
pulsation balloon + glucoproteins inhibitors resulted in
U$7508.1. An intervention with two left vessel was calculated
in US$10,910.2 and with two left vessel and one right vessel, the
cost increased to US$13,706.7. CONCLUSIONS: Our study
results showed high direct medical costs heterogeneity on diag-
nostic procedures in a Mexican hemodinamy service. These
results are useful for cost containment policies and for further
health economics researches in Mexico.
PCV22
INPATIENT MANAGEMENT OF TRANSMURAL AND
SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION
(AMI): DIFFERENCES IN RESOURCE USE AND COST
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OBJECTIVES: To identify number of transmural and subendo-
cardial AMI cases, as well as related inpatient resource use and
cost by type of AMI. METHODS: Reported all-payer 2003 
hospital data from six states (CA, FL, MD, MA, TX, WA) were
analyzed. Transmural (410.00–410.60, 410.01–410.61) and
subendocardial (410.70, 410.71) AMI cases were identiﬁed using
ICD-9 principal diagnosis codes. AMI cases with other (410.80,
410.81) or unspeciﬁed (410.90, 410.91) codes were identiﬁed,
but excluded. Demographics, length of stay, admission source,
AMI location, secondary diagnosis and procedure codes, DRG
assignment, disposition status and reported charges were ana-
lyzed. Charges (accommodations, ancillary services) adjusted by
a 0.65 cost-to-charge ratio, and for medical inﬂation and geo-
graphic factors to reﬂect national values are reported as costs
(2005US$). RESULTS: Of the 168,831 AMI cases identiﬁed,
more than half (56%) were coded as subendocardial (n =
94,625). Transmural AMI was coded for 35% (n = 59,123); 9%
were coded as other or unspeciﬁed AMI. The subendocardial
AMI group had more females (47% vs. 40%), was older (mean
age: 72, median: 75 years vs. mean: 68, median: 70 years), and
had a slightly longer LOS (mean: 5.8, median: 4 days vs. mean:
5.5, median: 3.7 days), on average, than those with a transmural
AMI. Signiﬁcantly (p < 0.01) fewer patients with subendocardial
AMI had ICU days (50% vs. 75%), and percutaneous coronary
(47% vs. 27%) and stent (8% vs. 6%) procedures. Coronary-
bypass surgery rate was the same (10%) for both groups. Inpa-
tient case fatality rate was signiﬁcantly (p < 0.01) higher for
transmural group (10% vs. 7%). The average cost per stay for
transmural AMI was $34,012 (median: $23,880); $28,483
(median: $18,664) for subendocardial AMI. CONCLUSIONS:
Substantially fewer cases of acute transmural infarct were
reported in this dataset. Yet, when reported, they were 
more lethal, resource intensive and costly than a subendocardial
AMI.
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AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF
DEEP VEIN THROMBOSIS (DVT) IN BRAZIL
Fonseca M,Araujo G
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OBJECTIVE: DVT is an important problem in clinical practice.
This study aims to estimate the costs of treatment of DVT from
the perspective of the private medicine payers in Brazil.
METHODS: To determine actual costs of patient management
the resource use collected during comparative clinical trials often
is insufﬁcient. Although large data bases can be used to estimate
patient health care resource consumption they are not always
available. One reasonable data source is soliciting expert opinion
from clinicians. Two Delphi panels one for vascular surgeons,
and another for intensivists were performed in order to delineate
practice patterns and to obtain resource utilization for routine
treatment and monitoring, adverse event management and other
clinical parameters representative of community physicians man-
aging of DVT. Responses were obtained from seven vascular sur-
geons and ﬁve intensivists from various centers in Brazil with
experience of treating DVT. Percentage likelihood of complica-
tions due to thromboprophylaxis was determined based upon
physician consensus. A decision analytic model was designed to
project the costs associated with venous thromboembolism.
RESULTS: The detected mean cost (in Brazilian Reais) of DVT
was R$9895.23. The detected cost of diagnosing DVT was
R$74.01, the treatment cost without considering itxs complica-
tions was R$5208.76 and the complications cost, balanced by
incidence was R$4612.46. The cost to avoid a DVT by the use
of a thromboprophylaxis was R$177.68. CONCLUSIONS:
DVT costs are only a part of the costs incurred in treating high
risk surgical or clinical patients. These results clearly show the
substantial costs that a DVT may represent in the treatment 
of these patients that may be prevented by the use of 
thromboprophylaxis.
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OBJECTIVES: This study was designed to investigate how
African American patients respond to DTCA of prescription
drug Lipitor® and the relationships between potential inﬂuenc-
ing variables and patients’ responses. METHODS: Face-to-face
interview was employed for this study, and a convenience sample
consisting of 160 African American patients were interviewed at
a general medicine clinic in a public hospital. Short-Test of Func-
tional Health Literacy in Adults (S-TOFHLA) was administered
to all study participants. Then the participants were asked to
view a TV advertisement of Lipitor®, followed by DTCA-related
interviews. Patients’ demographic and socioeconomic informa-
tion was also collected during the interviews. Bivariate analyses
and logistic regressions were used to assess the relationships
between potential inﬂuencing variables and patients’ responses
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to DTCA. RESULTS: After watching the TV advertisement of
Lipitor®, 89.3% of study participants agreed that they would
talk to their physicians about their cholesterol, 88.7% agreed
that they would ask their physicians to test their cholesterol
levels, and 47.3% agreed that they would ask their doctors to
write them a prescription for Lipitor®. The study also found that
26.0% of study participants had inadequate functional health lit-
eracy, 17.3% had marginal functional health literacy, and 56.7%
had adequate health literacy. Participants who rated the adver-
tisement as helpful responded more favorably to it. Older
patients were more likely to agree to talk to doctors about cho-
lesterol. Those who had a history of high cholesterol were more
likely to agree to ask doctors to test their cholesterol levels.
CONCLUSIONS: African American patients in this study
responded more favorably to DTCA. DTCA may be an effective
marketing tool for pharmaceutical companies. However, the net
public health and economic effects of DTCA remain to be 
determined.
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OBJECTIVE: Surveys have indicated that use of alternative
treatments is increasing in the United States. One survey in found
that 33.8% of Americans were using some form of alternative
medicine and a later survey found that use had increased to
42.1% in 1997. The objective is to provide an estimate of the
prevalence of Complementary and Alternate Medicine (CAM)
use by hypertensive patients in the United States. METHODS:
Cross-sectional analysis of the 2001–2003 Medical Expenditure
Panel Survey, a nationally representative sample of the U.S. non-
institutionalized civilian population. Patients with hypertension
were identiﬁed by ICD-9-CM code of 401. Use and costs of
CAM in patients with hypertension were compared with those
in non-hypertensive individuals. Student’s t test statistics was
used to compare the costs associated with CAM use between the
two groups. Multiple logistic regression was used to determine
independent predictors of CAM use in individuals with hyper-
tension, controlling for age, sex, race/ethnicity, household
income, educational level, and co-morbidity. RESULTS: Individ-
uals with hypertension were 1.3 times more likely to use CAM
than individuals without hypertension (8 vs. 5%, P < 0.0001).
The data showed that the prevalence of CAM use among hyper-
tensives not living in metropolitan statistical areas was twice that
of living in metropolitan statistical areas (2.9% vs 1.5%; P =
0.02). Among individuals with hypertension, older age (65 years)
and higher educational attainment were independently associ-
ated with CAM use. The mean amount in dollars spent per
person for CAM was not different in both groups ($414 ± 269
vs. $236 ± 26, P = 0.5106). CONCLUSIONS: These ﬁndings
have many implications for the way we understand CAM use
among hypertensives, both for clinical applications and future
research. The data provide a baseline estimate of CAM use
among hypertensives in the United States.
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PRESCRIBING PATTERNS FOR ANTIHYPERTENSIVE DRUGS
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LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK
TRIAL (ALLHAT) IN REGION EMILIA ROMAGNA (RER), ITALY
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OBJECTIVES: The ALLHAT ﬁndings (December 2002) recom-
mended thiazide-type diuretics for ﬁrst-step therapy in uncom-
plicated hypertensive patients, rather than either calcium channel
blockers (CCBs) or angiotensin-converting enzyme (ACE)
inhibitors. The objective of this study was to examine prescrib-
ing patterns for antihypertensive agents in Region Emilia
Romagna (RER), Italy, following the ALLHAT publication.
METHODS: We studied automated pharmacy claims of approx-
imately 4 million RER residents between January 1, 2000 and
December 31, 2003. We computed the monthly relative per-
centage of ﬁlled prescriptions for six antihypertensive classes: thi-
azide-type diuretics, ACE inhibitors or angiotensin receptor
blockers (ARBs), CCBs, beta-blockers, alpha-blockers, and
other-type antihypertensive diuretics. A stepwise auto-regressive
forecasting model was used for time series analysis. To assess the
impact of the ALLHAT guidelines on use of each antihyperten-
sive class, predicted relative percentages and 95% conﬁdence
intervals were calculated for the 12 months of 2003. RESULTS:
During the study period, ACE inhibitors/ARBs and CCBs had
the largest relative percentages (approximately 40% and 30%,
respectively), while the relative percentages for beta-blockers and
thiazide-type diuretics were roughly 10% and 1%, respectively.
Use of thiazide-type diuretics and ACE inhibitors/ARBs showed
an overall upward trend, which was not statistically associated
with the ALLHAT publication. The relative percentage of CCBs
diminished over time and was statistically signiﬁcant compared
with that predicted by the time-series model in the last four
months of 2003 (p < 0.05). The percentage of beta-blockers was
stable during the study period, although statistically signiﬁcantly
higher in the last 7 months of 2003 compared with the predicted
values (p < 0.05). Use of alpha-blockers and other-type antihy-
pertensive diuretics was steady over time. CONCLUSIONS: The
well-publicized ALLHAT ﬁndings had a limited impact on the
prescribing patters of antihypertensive drugs in Italy. Further
research should investigate why physicians appeared to be unre-
sponsive to the new clinical evidence.
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OBJECTIVES: Statins reduce morbidity and mortality in the
prevention of cardiovascular disease (CVD). Clinical trials have
shown that the lower the cholesterol level obtained, the lower
the risk of (CVD). Therefore, the use of high doses of statins is
often encouraged. Rosuvastatin is the most potent statin but cho-
lesterol changes obtained with the lower doses can also be
reached by increasing the dose of atorvastatin or simvastatin.
The aim of this study is to assess the impact of dose increases on
the cost-effectiveness of statins in Belgium. METHODS: A state-
transition model with a 20-year time horizon using 6-month
cycles was developed in MSExcel. Individuals enter the model
CVD free. Depending on age, smoking status, systolic blood
pressure, total cholesterol (TC) and HDL-cholesterol, CVD risk
(cardiac death, non-fatal MI, angina, fatal and non-fatal stroke)
was calculated using the SCORE equation. The STELLAR-study,
which compared the efﬁcacy of rosuvastatin, atorvastatin, and
simvastatin across doses, served as data source (reduction in TC
with 10mg rosuvastatin, 20mg atorvastatin and 80mg simvas-
tatin approximately equal). Ofﬁcial sources for cost of events
and costs of the different statins were used (Belgian payers per-
spective). 3% discounting was applied on costs and effects.
